- Trials with a EudraCT protocol (44)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44 result(s) found for: Lactation.
Displaying page 1 of 3.
EudraCT Number: 2018-004680-31 | Sponsor Protocol Number: 2018-004680-31 | Start Date*: 2019-08-16 | ||||||||||||||||
Sponsor Name:Lene Ringholm | ||||||||||||||||||
Full Title: A randomised controlled trial comparing the effect of the faster-acting insulin analog - insulin Fiasp® – versus insulin Novorapid® in the treatment of women with type 1 or type 2 diabetes during p... | ||||||||||||||||||
Medical condition: Type 1 and type 2 diabetes during pregnancy and lactation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005751-27 | Sponsor Protocol Number: X213220 | Start Date*: 2016-05-18 |
Sponsor Name:XOMA (US) LLC | ||
Full Title: A Multi-Center, Open-Label, Randomized, Single-Dose, Controlled Trial of Intravenously Administered XOMA 213 in Suppression of Lactation after Delivery in Postpartum Women | ||
Medical condition: Suppression of Lactation after Delivery in Postpartum Women | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001910-33 | Sponsor Protocol Number: AGAL02603 | Start Date*: 2007-12-05 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: A Multicenter, Multinational Study of the Effects of Fabrazyme® (agalsidase beta) Treatment on Lactation and Infants | |||||||||||||
Medical condition: Fabry disease | |||||||||||||
|
|||||||||||||
Population Age: In utero, Newborns, Infants and toddlers, Children, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) AT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019372-72 | Sponsor Protocol Number: MV22970 | Start Date*: 2010-04-16 | |||||||||||
Sponsor Name:Pharmahungary Group | |||||||||||||
Full Title: An Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza during Lactation. | |||||||||||||
Medical condition: Lactating women who present with clinical symptoms indicative of influenza will be recruited to receive immediate treatment with oseltamivir at a standard dose of 75 mg twice daily. These subjects ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007003-33 | Sponsor Protocol Number: ALID01803 | Start Date*: 2010-09-16 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: A Multicenter, Multinational, Open-Label Study of the Effects of Aldurazyme(laronidase) Treatment on Lactation in Women with Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants | |||||||||||||
Medical condition: mucocopolysaccharidoses I | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000902-31 | Sponsor Protocol Number: ECACOR19 | Start Date*: 2019-09-05 |
Sponsor Name:OMEQUI | ||
Full Title: Healing efficacy after impacted mandibular third molar surgery with the use of autologous platelet-rich fibrin: a randomized controlled clinical study | ||
Medical condition: If the addition of L-PRF reduces postoperative pain and inflammation, as well as complications, after extraction of lower third molars | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-009177-10 | Sponsor Protocol Number: BAY86-5016/14348 | Start Date*: 2009-04-30 |
Sponsor Name:Bayer HealthCare AG | ||
Full Title: Multicenter, open-label, randomized study to evaluate inhibition of ovulation of two transdermal patch formulations containing 0.55 mg ethinylestradiol and either 1.05 or 2.1 mg gestodene in health... | ||
Medical condition: The trial will be performed in healthy female volunteers. The intended indication is femal contraception. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-001198-13 | Sponsor Protocol Number: 310805 | Start Date*: 2008-08-19 |
Sponsor Name:Bayer HealthCare AG/Bayer Schering Pharma AG | ||
Full Title: Multicenter, open-label, randomized, uncontrolled study to evaluate inhibition of ovulation of two transdermal patch formulations containing 0.55 mg ethinylestradiol and either 1.05 or 2.1 mg gesto... | ||
Medical condition: The trial will be performed in healthy female volunteers. The indended indication is female contraception. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-002247-30 | Sponsor Protocol Number: RC31/21/0217 | Start Date*: 2021-09-24 |
Sponsor Name:CHU TOULOUSE | ||
Full Title: Evaluation of Amoxicillin diffusion in breast milk according to a population pharmacokinetic approach. | ||
Medical condition: Breastfeeding | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002425-34 | Sponsor Protocol Number: T160/2018 | Start Date*: 2019-09-06 | |||||||||||
Sponsor Name:Turku University Hospital | |||||||||||||
Full Title: LIRAGLUTIDE IN THE PREVENTION OF T2DM AFTER GESTATIONAL DIABETES | |||||||||||||
Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000893-27 | Sponsor Protocol Number: SJ2021016 | Start Date*: 2021-04-27 |
Sponsor Name:AZ Sint-Jan Brugge-Oostende AV | ||
Full Title: COVID-19: study to detect transfer of SARS-Cov-2 antibodies in breastmilk | ||
Medical condition: pregnancy lactating mothers | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000440-22 | Sponsor Protocol Number: Version17032021 | Start Date*: 2021-03-25 |
Sponsor Name:Universiteit Antwerpen | ||
Full Title: Vaccination against COVID-19 in Pregnant and Lactating Women in Belgium | ||
Medical condition: Vaccine responses to COVID19 vaccines administered in pregnant and lactating women | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-000821-31 | Sponsor Protocol Number: 307969 | Start Date*: 2004-11-16 |
Sponsor Name:Schering AG | ||
Full Title: Multi-center, open, randomized, parallel group comparison of cycle control for seven cycles and endometrial safety in a subgroup for thirteen cycles of contraceptive patch SH P00331F (0.9 mg ethiny... | ||
Medical condition: Contraception | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FI (Completed) ES (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003274-32 | Sponsor Protocol Number: 2015/233 | Start Date*: 2016-07-13 |
Sponsor Name:Dra Maria Luz Couce [...] | ||
Full Title: Effect of caffeine citrate in acute bronchiolitis symptoms of apnea in neonates and infants during the first three months of life | ||
Medical condition: Children under 3 years with acute RSV bronchiolitis which present breaks apnea | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002713-35 | Sponsor Protocol Number: AXCT01-01-03-2013 | Start Date*: 2014-07-29 | |||||||||||
Sponsor Name:MediPsych SA | |||||||||||||
Full Title: Randomized, controlled trial of the effectiveness of add-on tolcapone to usual antipsychotic therapy on cognitive and negative symptoms of patients with schizophrenia genotyped for COMT polymorphisms | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004657-11 | Sponsor Protocol Number: VI-Plt-01 | Start Date*: 2012-03-30 | |||||||||||
Sponsor Name:FONDAZIONE PROGETTO EMATOLOGIA | |||||||||||||
Full Title: Open label multicenter study of Eltrombopag for the treatment of Immune ThrombocytoPenia (ITP) secondary to Chronic Lymphoproliferative Disorders (LPDs) | |||||||||||||
Medical condition: Immune ThrombocytoPenia (ITP) secondary to Chronic Lymphoproliferative Disorders (LPDs) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001513-33 | Sponsor Protocol Number: CF111/204 | Start Date*: 2013-06-04 | |||||||||||
Sponsor Name:Laboratorios León Farma S.A. | |||||||||||||
Full Title: Phase II trial to evaluate the maintenance of ovulation inhibition with LF111 (drospirenone 4.0 mg 24/4 regimen) after scheduled 24-hour delays in pill intake. | |||||||||||||
Medical condition: Evaluation of ovulation inhibition with scheduled 24h delay in pill intake in healty young females of child bearing potential. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003219-26 | Sponsor Protocol Number: MR-130A-01-TD-2001 | Start Date*: 2023-01-10 | |||||||||||
Sponsor Name:Mylan Pharmaceuticals, Inc | |||||||||||||
Full Title: An open-label, phase II, dose-finding study of three dose strengths of MR-130A-01 contraceptive transdermal patch containing norelgestromin (NGMN) in healthy pre-menopausal women | |||||||||||||
Medical condition: Investigation of ovulation inhibition for indication of contraception in healthy subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006639-24 | Sponsor Protocol Number: 2020/ABM/01/00080 | Start Date*: 2022-10-19 |
Sponsor Name:The Cardinal Stefan Wyszyński Institute of Cardiology | ||
Full Title: Multicenter Polish Study of the Use of Bromocriptine in Perinatal Cardiomyopathy. New BioMarkers in the Early Diagnosis of Peripartum CardioMyopathy. PolBrom-PPCM | ||
Medical condition: PeriPartum Cardiomiopathy | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: PL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004509-29 | Sponsor Protocol Number: 2012-776 | Start Date*: 2015-11-03 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: Antidepressant treatments during pregnancy and lactation: prediction of drug exposure through breastfeeding and evaluation of drug effect on the neonatal adaptation and the development of the youn... | |||||||||||||
Medical condition: depression | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
